These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22901957)

  • 41. Changes in cerebral activations during movement execution and imagery after parietal cortex TMS interleaved with 3T MRI.
    de Vries PM; de Jong BM; Bohning DE; Walker JA; George MS; Leenders KL
    Brain Res; 2009 Aug; 1285():58-68. PubMed ID: 19523932
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bilateral impairments of skilled reach-to-eat in early Parkinson's disease patients presenting with unilateral or asymmetrical symptoms.
    Doan JB; Melvin KG; Whishaw IQ; Suchowersky O
    Behav Brain Res; 2008 Dec; 194(2):207-13. PubMed ID: 18692094
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of levodopa on both verbal and motor representations of action in Parkinson's disease: a fMRI study.
    Péran P; Nemmi F; Méligne D; Cardebat D; Peppe A; Rascol O; Caltagirone C; Demonet JF; Sabatini U
    Brain Lang; 2013 Jun; 125(3):324-9. PubMed ID: 22841350
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Within-session and between-session reproducibility of cerebral sensorimotor activation: a test--retest effect evidenced with functional magnetic resonance imaging.
    Loubinoux I; Carel C; Alary F; Boulanouar K; Viallard G; Manelfe C; Rascol O; Celsis P; Chollet F
    J Cereb Blood Flow Metab; 2001 May; 21(5):592-607. PubMed ID: 11333370
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease.
    Barone P; Lamb J; Ellis A; Clarke Z
    Mov Disord; 2007 Mar; 22(4):483-9. PubMed ID: 17115380
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study.
    Rektorova I; Balaz M; Svatova J; Zarubova K; Honig I; Dostal V; Sedlackova S; Nestrasil I; Mastik J; Bares M; Veliskova J; Dusek L
    Clin Neuropharmacol; 2008; 31(5):261-6. PubMed ID: 18836343
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of the supplementary motor area in the automatic activation of motor plans in de novo Parkinson's disease patients.
    D'Ostilio K; Deville B; Cremers J; Grandjean J; Skawiniak E; Delvaux V; Garraux G
    Neurosci Res; 2013 Jul; 76(3):173-7. PubMed ID: 23643464
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Amnestic mild cognitive impairment in Parkinson's disease: a brain perfusion SPECT study.
    Nobili F; Abbruzzese G; Morbelli S; Marchese R; Girtler N; Dessi B; Brugnolo A; Canepa C; Drosos GC; Sambuceti G; Rodriguez G
    Mov Disord; 2009 Feb; 24(3):414-21. PubMed ID: 19235928
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Amplitude of low-frequency oscillations in Parkinson's disease: a 2-year longitudinal resting-state functional magnetic resonance imaging study.
    Hu XF; Zhang JQ; Jiang XM; Zhou CY; Wei LQ; Yin XT; Li J; Zhang YL; Wang J
    Chin Med J (Engl); 2015 Mar; 128(5):593-601. PubMed ID: 25698189
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differential effects of dopaminergic medication on basic motor performance and executive functions in Parkinson's disease.
    Michely J; Barbe MT; Hoffstaedter F; Timmermann L; Eickhoff SB; Fink GR; Grefkes C
    Neuropsychologia; 2012 Aug; 50(10):2506-14. PubMed ID: 22776611
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cortical thickness in de novo patients with Parkinson disease and mild cognitive impairment with consideration of clinical phenotype and motor laterality.
    Danti S; Toschi N; Diciotti S; Tessa C; Poletti M; Del Dotto P; Lucetti C
    Eur J Neurol; 2015 Dec; 22(12):1564-72. PubMed ID: 26212370
    [TBL] [Abstract][Full Text] [Related]  

  • 52. BoNT-A related changes of cortical activity in patients suffering from severe hand paralysis with arm spasticity following ischemic stroke.
    Veverka T; Hluštík P; Tomášová Z; Hok P; Otruba P; Král M; Tüdös Z; Zapletalová J; Herzig R; Krobot A; Kaňovský P
    J Neurol Sci; 2012 Aug; 319(1-2):89-95. PubMed ID: 22687958
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease.
    Singer C; Lamb J; Ellis A; Layton G;
    Mov Disord; 2007 Mar; 22(4):476-82. PubMed ID: 17318839
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
    Fera F; Nicoletti G; Cerasa A; Romeo N; Gallo O; Gioia MC; Arabia G; Pugliese P; Zappia M; Quattrone A
    Brain Res Bull; 2007 Sep; 74(1-3):75-83. PubMed ID: 17683792
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Compensatory fronto-parietal hyperactivation during set-shifting in unmedicated patients with Parkinson's disease.
    Gerrits NJ; van der Werf YD; Verhoef KM; Veltman DJ; Groenewegen HJ; Berendse HW; van den Heuvel OA
    Neuropsychologia; 2015 Feb; 68():107-16. PubMed ID: 25576907
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacologically modulated fMRI--cortical responsiveness to levodopa in drug-naive hemiparkinsonian patients.
    Buhmann C; Glauche V; Stürenburg HJ; Oechsner M; Weiller C; Büchel C
    Brain; 2003 Feb; 126(Pt 2):451-61. PubMed ID: 12538411
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ropinirole treatment in Parkinson's disease associated with higher serum level of inflammatory biomarker NT-proCNP.
    Tomasiuk R; Szlufik S; Friedman A; Koziorowski D
    Neurosci Lett; 2014 Apr; 566():147-50. PubMed ID: 24602984
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increased Cognitive Control During Execution of Finger Tap Movement in People with Parkinson's Disease.
    Mak MK; Cheung V; Ma S; Lu ZL; Wang D; Lou W; Shi L; Mok VC; Chu WC; Hallett M
    J Parkinsons Dis; 2016 Jun; 6(3):639-50. PubMed ID: 27372216
    [TBL] [Abstract][Full Text] [Related]  

  • 59. I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging.
    Goetz CG; Vaughan CL; Goldman JG; Stebbins GT
    Mov Disord; 2014 Jan; 29(1):115-7. PubMed ID: 23843193
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cortical activity in Parkinson's disease during executive processing depends on striatal involvement.
    Monchi O; Petrides M; Mejia-Constain B; Strafella AP
    Brain; 2007 Jan; 130(Pt 1):233-44. PubMed ID: 17121746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.